Literature DB >> 25189423

Menstrual pain and epithelial ovarian cancer risk.

Ana Babic1, Daniel W Cramer, Linda J Titus, Shelley S Tworoger, Kathryn L Terry.   

Abstract

PURPOSE: Menstrual pain is associated with increased production of inflammatory molecules, such as prostaglandins. Inflammation is involved in pathogenesis of several cancers, including ovarian cancer. In this study, we examined the association between menstrual pain and risk of ovarian cancer.
METHODS: We conducted a case-control study with 2,028 cases of epithelial ovarian cancer and 2,091 age- and study center-matched controls. Women were asked to report the severity of menstrual pain during their twenties and thirties, when not using oral contraceptives or breastfeeding. We used an unconditional logistic regression to evaluate the association between menstrual pain and epithelial ovarian cancer risk overall, and polytomous logistic regression to evaluate whether the association differed across tumor subtypes.
RESULTS: Risk of ovarian cancer was increased in women with moderate (OR 1.22, 95 % CI 1.05-1.42) and severe pain (OR 1.34, 95 % CI 1.09-1.65) compared to women with no or mild pain during menstrual period. The association differed by histologic subtypes, with significant associations for severe pain with endometrioid (OR 1.64, 95 % CI 1.15-2.34) and clear cell tumors (OR 1.91, 95 % CI 1.11-3.28).
CONCLUSIONS: Our data suggest that moderate and severe pain during menstrual period are associated with increased risk of epithelial ovarian cancer. Due to high prevalence of menstrual pain in women of reproductive age, this observation warrants further studies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25189423      PMCID: PMC4500123          DOI: 10.1007/s10552-014-0463-6

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  49 in total

1.  Risk factors for epithelial ovarian cancer in Beijing, China.

Authors:  Y Chen; P C Wu; J H Lang; W J Ge; P Hartge; L A Brinton
Journal:  Int J Epidemiol       Date:  1992-02       Impact factor: 7.196

Review 2.  Dysmenorrhea.

Authors:  M Y Dawood
Journal:  Clin Obstet Gynecol       Date:  1990-03       Impact factor: 2.190

3.  Menstrual-PGF2 alpha, PGE2 and TXA2 in normal and dysmenorrheic women and their temporal relationship to dysmenorrhea.

Authors:  A M Powell; W Y Chan; P Alvin; I F Litt
Journal:  Prostaglandins       Date:  1985-02

4.  Leukotriene release by endometrium and myometrium throughout the menstrual cycle in dysmenorrhoea and menorrhagia.

Authors:  M C Rees; V DiMarzo; J R Tippins; H R Morris; A C Turnbull
Journal:  J Endocrinol       Date:  1987-05       Impact factor: 4.286

5.  Hypothesis testing in the polychotomous logistic model with an application to detecting gastrointestinal cancer.

Authors:  R J Marshall; E M Chisholm
Journal:  Stat Med       Date:  1985 Jul-Sep       Impact factor: 2.373

6.  Endometriosis: its association with retrograde menstruation, dysmenorrhoea and tubal pathology.

Authors:  D T Liu; A Hitchcock
Journal:  Br J Obstet Gynaecol       Date:  1986-08

7.  Risk of epithelial ovarian cancer in relation to benign ovarian conditions and ovarian surgery.

Authors:  Mary Anne Rossing; Kara L Cushing-Haugen; Kristine G Wicklund; Jennifer A Doherty; Noel S Weiss
Journal:  Cancer Causes Control       Date:  2008-08-14       Impact factor: 2.506

8.  Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea.

Authors:  S Nigam; C Benedetto; M Zonca; I Leo-Rossberg; H Lübbert; J Hammerstein
Journal:  Eicosanoids       Date:  1991

9.  Tubal sterilization, hysterectomy, and the subsequent occurrence of epithelial ovarian cancer.

Authors:  K L Irwin; N S Weiss; N C Lee; H B Peterson
Journal:  Am J Epidemiol       Date:  1991-08-15       Impact factor: 4.897

Review 10.  Eicosanoids in primary dysmenorrhea, endometriosis and menstrual migraine.

Authors:  C Benedetto
Journal:  Gynecol Endocrinol       Date:  1989       Impact factor: 2.260

View more
  4 in total

1.  Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium.

Authors:  Ana Babic; Holly R Harris; Allison F Vitonis; Linda J Titus; Susan J Jordan; Penelope M Webb; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Kristine Wicklund; Marc T Goodman; Francesmary Modugno; Kirsten B Moysich; Roberta B Ness; Susanne K Kjaer; Joellen Schildkraut; Andrew Berchuck; Celeste L Pearce; Anna H Wu; Daniel W Cramer; Kathryn L Terry
Journal:  Int J Cancer       Date:  2017-09-21       Impact factor: 7.396

2.  PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.

Authors:  Cristian Rodriguez-Aguayo; Emine Bayraktar; Cristina Ivan; Burcu Aslan; Junhua Mai; Guangan He; Lingegowda S Mangala; Dahai Jiang; Archana S Nagaraja; Bulent Ozpolat; Arturo Chavez-Reyes; Mauro Ferrari; Rahul Mitra; Zahid H Siddik; Haifa Shen; Xianbin Yang; Anil K Sood; Gabriel Lopez-Berestein
Journal:  EBioMedicine       Date:  2019-01-14       Impact factor: 11.205

3.  Common Analgesic Use for Menstrual Pain and Ovarian Cancer Risk.

Authors:  Naoko Sasamoto; Ana Babic; Allison F Vitonis; Linda Titus; Daniel W Cramer; Britton Trabert; Shelley S Tworoger; Kathryn L Terry
Journal:  Cancer Prev Res (Phila)       Date:  2021-07-09

4.  Assessment of gynecological and lifestyle-related risk factors of ovarian cancer.

Authors:  Gazala Abdulaziz; Natalia Anna Welc; Emilia Gąsiorowska; Ewa Nowak-Markwitz
Journal:  Prz Menopauzalny       Date:  2021-12-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.